Casey Woodring
Stock Analyst at JP Morgan
(0.81)
# 4,034
Out of 5,182 analysts
61
Total ratings
24.32%
Success rate
-13.97%
Average return
Main Sectors:
Stocks Rated by Casey Woodring
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ILMN Illumina | Maintains: Neutral | $120 → $125 | $135.78 | -7.94% | 4 | May 1, 2026 | |
| QGEN Qiagen | Maintains: Overweight | $60 → $45 | $34.25 | +31.39% | 6 | Apr 29, 2026 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $165 → $160 | $165.78 | -3.49% | 11 | Apr 13, 2026 | |
| RVTY Revvity | Maintains: Neutral | $105 → $96 | $86.68 | +10.75% | 1 | Mar 31, 2026 | |
| TEM Tempus AI | Maintains: Neutral | $80 → $60 | $55.00 | +9.09% | 2 | Feb 25, 2026 | |
| GH Guardant Health | Maintains: Overweight | $120 → $130 | $87.60 | +48.40% | 3 | Feb 20, 2026 | |
| IQV IQVIA Holdings | Maintains: Overweight | $255 → $225 | $157.77 | +42.61% | 2 | Feb 6, 2026 | |
| NTRA Natera | Maintains: Overweight | $250 → $260 | $207.28 | +25.43% | 3 | Dec 15, 2025 | |
| BRKR Bruker | Maintains: Overweight | $50 → $55 | $36.79 | +49.50% | 1 | Dec 15, 2025 | |
| BLLN BillionToOne | Maintains: Overweight | $150 → $145 | $77.49 | +87.12% | 2 | Dec 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $165 → $180 | $114.52 | +57.18% | 2 | Nov 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $26 → $22 | $12.64 | +74.05% | 5 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $15 | $22.43 | -33.13% | 1 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $16 | $15.50 | +3.23% | 3 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $12 | $7.96 | +50.75% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $300 → $325 | $307.12 | +5.82% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $600 → $650 | $469.21 | +38.53% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,200 → $1,285 | $1,267.07 | +1.42% | 1 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $265 → $150 | $112.85 | +32.92% | 6 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7 → $6 | $2.95 | +103.39% | 3 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $25 → $23 | $26.13 | -11.98% | 2 | Oct 31, 2023 |
Illumina
May 1, 2026
Maintains: Neutral
Price Target: $120 → $125
Current: $135.78
Upside: -7.94%
Qiagen
Apr 29, 2026
Maintains: Overweight
Price Target: $60 → $45
Current: $34.25
Upside: +31.39%
Charles River Laboratories International
Apr 13, 2026
Maintains: Neutral
Price Target: $165 → $160
Current: $165.78
Upside: -3.49%
Revvity
Mar 31, 2026
Maintains: Neutral
Price Target: $105 → $96
Current: $86.68
Upside: +10.75%
Tempus AI
Feb 25, 2026
Maintains: Neutral
Price Target: $80 → $60
Current: $55.00
Upside: +9.09%
Guardant Health
Feb 20, 2026
Maintains: Overweight
Price Target: $120 → $130
Current: $87.60
Upside: +48.40%
IQVIA Holdings
Feb 6, 2026
Maintains: Overweight
Price Target: $255 → $225
Current: $157.77
Upside: +42.61%
Natera
Dec 15, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $207.28
Upside: +25.43%
Bruker
Dec 15, 2025
Maintains: Overweight
Price Target: $50 → $55
Current: $36.79
Upside: +49.50%
BillionToOne
Dec 10, 2025
Maintains: Overweight
Price Target: $150 → $145
Current: $77.49
Upside: +87.12%
Nov 25, 2025
Maintains: Overweight
Price Target: $165 → $180
Current: $114.52
Upside: +57.18%
Nov 7, 2025
Maintains: Underweight
Price Target: $26 → $22
Current: $12.64
Upside: +74.05%
Nov 7, 2025
Maintains: Neutral
Price Target: $13 → $15
Current: $22.43
Upside: -33.13%
Nov 5, 2025
Maintains: Neutral
Price Target: $14 → $16
Current: $15.50
Upside: +3.23%
Oct 30, 2025
Downgrades: Neutral
Price Target: $14 → $12
Current: $7.96
Upside: +50.75%
Oct 9, 2025
Maintains: Neutral
Price Target: $300 → $325
Current: $307.12
Upside: +5.82%
Oct 9, 2025
Maintains: Overweight
Price Target: $600 → $650
Current: $469.21
Upside: +38.53%
Oct 9, 2025
Maintains: Neutral
Price Target: $1,200 → $1,285
Current: $1,267.07
Upside: +1.42%
Apr 29, 2025
Downgrades: Neutral
Price Target: $265 → $150
Current: $112.85
Upside: +32.92%
May 13, 2024
Maintains: Neutral
Price Target: $7 → $6
Current: $2.95
Upside: +103.39%
Oct 31, 2023
Maintains: Neutral
Price Target: $25 → $23
Current: $26.13
Upside: -11.98%